Azaheteroaryl compound and application thereof

A compound as shown in formula (I), a pharmaceutically acceptable salt, hydrate, stereoisomer, or solvate thereof:

• wherein
• A is
• R01, R02 and R03 are each independently hydrogen or halogen;
• n is 0;
• m is 1 or 2;
• X is N;
• R1 is any one of the following structures:
• X1 is independently C or N;
• X2 is independently N or CR2;
• X3 is independently N or CR3;
• X4 is independently N or CR4;
• X8 is independently CR8 or N;
• X9 is independently N or CR9;
• R2 is H, halogen, —CN, —NRaRb, C1-4 alkyl, C1-4 alkyl substituted with 1, 2 or 3 R5 groups, C1-4 haloalkyl, C1-4 alkoxy, C3-6 heterocycloalkyl, C3-6 heterocycloalkyl substituted with 1, 2 or 3 R5 groups, C3-6 heterospirocycloalkyl, —CO2R16, —C(═O) NR16R17, or —NRaRb;
• each R16 and R17 are independently H or C1-4 alkyl;
• Ra and Rb are independently H or C1-4 alkyl;
• each R5 is independently —OH, C1-4 alkyl, C1-4 alkoxy, C1-4 alkoxy substituted with 1, 2 or 3 hydroxyl groups, —NRa1Rb1, C3-6 heterocycloalkyl, C3-6 heterocycloalkyl substituted with 1, 2 or 3 C1-4 alkyl groups, C36 heterocycloalkyl substituted with 1, 2 or 3 C3-6 heterocycloalkyl groups, or C1-15 heteroaryl;
• Ra1 and Rb1 are independently H, C1-4 alkyl, C1-4 alkyl substituted with 1, 2 or 3 —NRa2Rb2 groups, or C1-4 alkyl substituted with 1, 2 or 3 hydroxyl groups;
• Ra2 and Rb2 are independently H or C1-4 alkyl;
• the heteroatom in the C3-6 heterocycloalkyl is selected from N, O and S, and the number of the heteroatom is 1, 2, 3 or 4;
• the heteroatom in the C3-6 heterospirocycloalkyl is selected from N, O and S, and the number of the heteroatom is 1, 2, 3 or 4;
• the heteroatom in the C1-15 heteroaryl is selected from N, O and S, and the number of the heteroatom is 1, 2, 3, 4, 5 or 6;
• R3 is H, halogen, —CN, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, or —C(═O) NR16R17;
• R4 is H, halogen, or C1-4 alkyl;
• R6 is H, halogen, —CN, C1-4 alkyl, C1-4 alkyl substituted with 1, 2 or 3 R5 groups, —CO2R16, —C(═O)NR16R17, —(C═O)R16, SO2R16, or —POR16R17;
• each R16 and each R17 are independently H, C1-4 alkyl, or C3-6 heterocycloalkyl;
• each R5 is independently —OH, —CN, —NRa1Rb1, C6-18 aryl, —C(═O)NR16aR17a, —CO2R16a, —O(C═O)R16a, —NH(C═O)R16a, or —(C═O)R16a;
• Ra1 and Rb1 are independently H or C1-4 alkyl;
• each R16a and R17a are independently H, C1-4 alkyl or C3-6 heterocycloalkyl;
• R7 is H, —OH, —NRaRb, C1-4 alkyl, C1-4 alkyl substituted with 1, 2 or 3 hydroxyl groups, C1-4 haloalkyl, —CO2R16, or —C(═O)NR16R17;
• Ra and Rb are independently H or C1-4 alkyl;
• R16 and R17 are independently H, C1-4 alkyl or C1-4 haloalkyl;
• R8 is H or C1-4 alkyl;
• R9 is H, halogen, or C1-4 alkyl;
• R10 is H, halogen, C1-4 alkyl, or C1-4 alkyl substituted with 1, 2 or 3 R5 groups;
• each R5 is independently —NRa1Rb1;
• Ra1 and Rb1 are independently H or C1-4 alkyl;
• R11 is H, halogen, or C1-4 alkyl;
• R12, R13, R14, and R15 are H.